Proteogenomics Consortium

Strategic partnership will enable more than a billion peptides to be cataloged to enable the discovery of new protein variants and novel biomarkers leading to therapeutic breakthroughs

The Proteogenomics Consortium will enable genomics customers to more easily add deep, unbiased proteomics data to their discovery, translational, and clinical studies. Through this effort, a capacity for more than one billion peptides to be analyzed and cataloged for discovery of new protein variants and novel biomarkers will be accessible to the market.

Through this multi-year effort, Seer and Sciex will contribute industry-leading proprietary proteomics technologies, and DLS will provide its significant scale and expertise in genomic services and biospecimens, to provide services that support population scale plasma proteogenomic projects.

Discovery Life Sciences will expand their existing biomarker discovery platform as part of their proteomics strategy, broadening the technology platforms available to their worldwide customer base.  Discovery’s unique service-oriented scientific team will deliver reliable scientific insights for proteogenomic studies.

Seer’s Proteograph Product Suite includes proprietary engineered nanoparticles, consumables, an automation instrument, and software that enables deep, unbiased proteomics studies with an unprecedented combination of speed, scale, and depth and breadth of data. It is designed to accurately survey thousands of proteins and millions of peptides with precision. 

The Sciex ZenoTOF 7600 System is a high-resolution, accurate mass system combining the power of Zeno trap pulsing with electron activated dissolution (EAD) fragmentation technology to uncover structural information, previously inaccessible, and drive the limits of quantification achievable with accurate mass.

The Proteogenomics Consortium aims to significantly contribute to expanded understanding of the proteome in an unbiased manner across a variety of cohorts and disease states. With a phased approach to building a 100,000 sample per- year capacity, the Proteogenomics Consortium will create the capacity, workflows, and expertise to run large scale proteogenomic projects efficiently, quickly and robustly. Through the consortium there is also an opportunity for future collaborations to further pave the way for adoption of proteogenomics via workflow optimization, joint publications and development of novel applications.

To begin a consultation or submit a project inquiry, please contact proteinbiomarkers@dls.com or fill out the contact form below.